Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 29, 2022 08:30 ET | Source: Galecto, Inc.

Galecto Completes Enrollment in Phase 1b/2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis

Top-line results from GULLIVER-2 trial on track for the fourth quarter of 2022 Part 1 of GULLIVER-2 trial completed with positive results as previously announced in December 2021 BOSTON, March 29,...
February 17, 2022 17:00 ET | Source: Galecto, Inc.

Galecto Reports Financial Results for the Year Ended December 31, 2021

Continued pipeline progress with three potentially first-in-class product candidates Strong cash position with cash runway into 2H 2024 BOSTON, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc....
February 07, 2022 08:00 ET | Source: Galecto, Inc.

Galecto to Participate at Upcoming Investor Conferences

BOSTON, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced...
January 27, 2022 07:00 ET | Source: Galecto, Inc.

Galecto Publishes Results Showing Safety and Efficacy of the GB0139 Inhaled Galectin-3 Inhibitor in Hospitalized COVID-19 Patients on Standard of Care

Results Support Favorable Safety and Tolerability Profile and Target Engagement of GB0139 and Potential for GB0139 in Severe Lung Disease Company Provides Update on GALACTIC-1 Trial BOSTON, Jan. ...
January 05, 2022 08:00 ET | Source: Galecto, Inc.

Galecto Adds Experienced Biotech Executive Stephanie Oestreich as Chief Business Officer

BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced...
December 20, 2021 08:00 ET | Source: Galecto, Inc.

Galecto Provides Enrollment Update on Phase 2a MYLOX-1 Trial and Reiterates Expected Timing of Multiple Data Readouts in 2022

Company has enrolled 10 of the targeted 16 patients in the trial Anticipates interim data in mid-2022 and topline data from full trial in 2H 2022 BOSTON, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Galecto,...
December 13, 2021 08:00 ET | Source: Galecto, Inc.

Galecto Announces Positive Preliminary Results for Oral Galectin-3 Inhibitor GB1211 in Part 1 of its Phase 1b/2a Liver Cirrhosis Trial

GB1211 observed to be safe and well tolerated in initial twelve randomized subjects, including six hepatically impaired liver cirrhosis patients Galecto initiates Part 2 of Phase 1b/2a trial in...
November 04, 2021 16:30 ET | Source: Galecto, Inc.

Galecto Reports Third Quarter Operating and Financial Results

Announces clinical collaboration with Roche for first line NSCLC Remains on track with clinical data milestone timing BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a...
November 02, 2021 08:00 ET | Source: Galecto, Inc.

Galecto Announces Clinical Collaboration with Roche for Phase 2 Trial of GB1211 in Combination with Atezolizumab in First Line Non-Small-Cell Lung Cancer

Upcoming Phase 2 trial marks expansion of Galecto pipeline into oncology and provides opportunity for exploring the use of galectin-3 inhibitors in cancer Additional information relating to...
October 28, 2021 08:00 ET | Source: Galecto, Inc.

Galecto Hosting a Key Opinion Leader Webinar on GB1211: A Potential Treatment For Non-Small Cell Lung Cancer

BOSTON, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced...